Trial: 202111001

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies



Principal Investigator

Adkins, Douglas

Disease Site

Breast; Cervix; Colon; Corpus Uteri; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Ovary; Prostate; Rectum; Stomach; Urinary Bladder

Learn more about this study at: